Radyus Research

Radyus Research is a private, service-oriented drug development organization that acts as an outsourced R&D partner for emerging biotech companies and venture funds. Its business model is centered on providing a fully integrated, cost-effective suite of services to accelerate client programs from early discovery to IND submission and early clinical trials. Since its 2020 founding, the company claims to have served over 50 clients across 12 countries, indicating rapid adoption and a global footprint. Radyus operates as a strategic service provider rather than developing its own therapeutic assets, positioning itself in the growing contract research and development market.

Integrated drug development service model leveraging a team with top-tier pharma experience. Provides end-to-end program management and execution across preclinical, clinical, CMC, and regulatory functions, acting as an outsourced R&D team for biotech clients.

Radyus competes in a fragmented market including large global CROs (e.g., IQVIA, PPD), specialized preclinical/clinical service providers, and boutique consulting firms. Its differentiation lies in the 'fully-integrated' model and strategic counsel, positioning it between traditional transactional CROs and high-cost management consultants. Success depends on demonstrating superior efficiency and outcomes compared to clients managing multiple vendors independently.